Globus Medical (GMED) Director James R. Tobin Exercises Options, Sells 30,000 Shares

What Happened

• James R. Tobin, a director of Globus Medical (GMED), exercised options to acquire 30,000 shares and sold 30,000 shares in an open-market transaction on September 15, 2026.
• Exercises: 15,000 shares @ $53.75 (cost $806,250) and 15,000 shares @ $63.68 (cost $955,200), total exercise cost $1,761,450.
• Sale: 30,000 shares sold in the open market at a weighted average price of $74.58 for total proceeds of $2,237,502 (shares sold across prices $74.33–$74.96 per footnote).

Key Details

• Transaction date: September 15, 2026.
• Exercise entries coded (M) = option exercises; sale coded (S) = open market sale.
• Two additional (M) entries are reported as dispositions at $0 for 15,000 shares each (reported as derivative dispositions in the filing).
• Footnotes: The sale price shown is a weighted average (sold in multiple trades between $74.33 and $74.96). The exercised options were granted Jan 26, 2024 and Jan 27, 2022 and are fully vested.
• Shares owned after the transaction: not disclosed in the provided excerpt.
• Filing timeliness: Form 4 was filed the next day (Sept 16, 2026) for transactions on Sept 15, 2026 — the filing appears timely.

Context

• Because Tobin exercised options and sold shares the same day, this sequence is effectively a same-day exercise and sale (often called a cashless or immediate sell after exercise); the filing shows both the acquisition via option exercise and the open-market sale.
• The two derivative dispositions reported at $0 may reflect net settlement or other option mechanics; the filing does not provide additional mechanics beyond the entries and footnotes.
• These are routine insider filings documenting option exercises and a contemporaneous open-market sale; they are factual records of activity, not explanations of motive.